Precision Medicine to Redefine Insulin Secretion and Monogenic Diabetes (PRISM): A Randomized Controlled Trial in Chinese Patients With Young-Onset Diabetes
Primary result · Composite of incident or progression of diabetes-related complicationsResult — go to the resultOdds ratio 0.908 95% CI 0.675–1.221Authors' conclusion
A 3-year technology-enhanced, multicomponent program improved cardiometabolic status, proxies of β-cell function, and PROMs in individuals with YOD but did not reduce complications.
Study context
- Population
- Chinese individuals aged 18 to 50 years with non-T1D diagnosed at age ≤40 years; mean (SD) age 40.7 (6.5) years
- Participants
- 884 individuals
- Comparison
- JADE-PRISM precision management vs usual clinic-based care
- JADE-PRISMn = 441
- JADE-onlyn = 443reference
- Primary endpoint
- Composite of:
- Incident
- Progression of all diabetes-related complications
- Follow-up
- 3 years
Methodological detailssingle-center, two-arm, 3-year
- Single-center
- Two-arm
- 3-year
Primary result
As reported in the abstract
Composite of:
- Incident
- Progression of diabetes-related complications
Odds ratio
0.908
95% CI 0.675–1.221
Events by treatment group
JADE-PRISMvs JADE-only
OR 0.908 (95% CI 0.675–1.221)
Secondary outcomes
Attainment of ≥3 treatment targets
P < 0.001
Proxies of β-cell function and emotional distress
- Improved proxies of β-cell function and reduced emotional distress with JADE-PRISM
Original publication
Precision Medicine to Redefine Insulin Secretion and Monogenic Diabetes (PRISM): A Randomized Controlled Trial in Chinese Patients With Young-Onset Diabetes. Diabetes Care. Published 12 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →